Physiology-based toxicokinetic modelling in the frame of the European Human Biomonitoring Initiative

Abstract

Given the opportunities provided by internal dosimetry modelling in the interpretation of human biomonitoring (HBM) data, the assessment of the links between exposure to chemicals and observed HBM data can be effectively supported by PBTK modelling. This paper gives a comprehensive review of available human PBTK models for compounds selected as a priority by the European Human Biomonitoring Initiative (HBM4EU). We highlight their advantages and deficiencies and suggest steps for advanced internal dose modelling. The review of the available PBTK models highlighted the conceptual differences between older models compared to the ones developed recently, reflecting commensurate differences in research questions. Due to the lack of coordinated strategies for deriving useful biomonitoring data for toxicokinetic properties, significant problems in model parameterisation still remain; these are further increased by the lack of human toxicokinetic data due to ethics issues.

Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications

“…Animal experimental models offer several advantages; they can support suspected epidemiological adverse outcomes and can generate awareness of potential health issues. Despite improvement of in vitro models, and of in silico tools such as quantitative structure-activity relationship (QSAR) and toxicokinetic models [633,634], currently, chemical hazard assessment practices are still dependent on in vivo data to confirm adverse effects of mixtures, data-poor chemicals, and metabolites, to generate guiding kinetic parameters for dose-response differences on absorption, distribution, metabolism, and excretion of substances, and identify tissues where substances accumulate and become toxicity-targets. Moreover, developmental and long-term effects cannot be predicted by current in vitro or in silico methods [206,635].…”

A Predictive Toxicokinetic Model for Nickel Leaching from Vascular Stents

“…59−63 The use of computational modeling and simulation (CM&S) in regulatory submissions is rapidly increasing and together with bench, nonclinical in vivo, and clinical studies can also be used to evaluate the toxicological safety and effectiveness of medical devices. 64,65 The FDA 66 and the EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 67 promote and facilitate the use of nonanimal methods in testing and research that have the potential to provide timelier and more predictive information to assess certain aspects of regulated products. For many years, CM&S studies have been employed to support engineering design and structural analysis 68−70 as they have the potential to streamline the development process and alleviate challenges related to premarket device evaluation.…”

Boosting knowledge and harmonisation in the mycotoxin field through sustainable scientific alliances – MYCOBOOST

“…These models help predict the bioavailability, distribution, metabolism, and elimination kinetics. In silico toxicokinetics methodologies could represent a reliable tool for better understanding the toxicokinetic properties, potential accumulation, and elimination of mycotoxins, also in support of biomonitoring methodologies (Grech et al 2017;Sarigiannis et al 2019;Lootens et al 2023) Computational methods and modelling techniques are employed for understanding toxicodynamics of target compounds, focusing on their interactions with biological targets, signalling pathways, and the resulting toxic effects. These approaches provide insights into the mechanisms of toxicity and aid in risk assessment.…”